Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis

Journal of Immunology

Volumn 190, Issue 8, 2013, Pages 3959-3966

  Rosen, Lindsey B ^a   Freeman, Alexandra F ^a   Yang, Lauren M ^a,b   Jutivorakool, Kamonwan ^a,c   Olivier, Kenneth N ^a   Angkasekwinai, Nasikarn ^d   Suputtamongkol, Yupin ^d   Bennett, John E ^a   Pyrgos, Vasilios ^a   Williamson, Peter R ^a   Ding, Li ^a   Holland, Steven M ^a   Browne, Sarah K ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AUTOANTIBODY; CYTOKINE ANTIBODY; FLUCONAZOLE; FLUCYTOSINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; IMMUNOGLOBULIN G; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; STAT5 PROTEIN;

ADULT; ANTIBODY DETECTION; ARTICLE; BLOOD EXAMINATION; CEREBROSPINAL FLUID EXAMINATION; CLINICAL ARTICLE; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG ALVEOLUS PROTEINOSIS; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

ADULT; AUTOANTIBODIES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN G; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; STAT5 TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 84875976539     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202526     Document Type: Article

References (52)

1. Kitamura, T., N. Tanaka, and J. Watanabe, U. Uchida, S. Kanegasaki, Y. Yamada, and K. Nakata. 1999. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 190: 875-880.
2. Tanaka, N., J. Watanabe, T. Kitamura, Y. Yamada, S. Kanegasaki, and K. Nakata. 1999. Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor. FEBS Lett. 442: 246-250.
3. Andersen, B. R., R. E. Ecklund, and W. F. Kellow. 1960. Pulmonary alveolar proteinosis with systemic nocardiosis. A case report. JAMA 174: 28-31.
4. Bergman, F., and F. Linell. 1961. Cryptococcosis as a cause of pulmonary alveolar proteinosis. Acta Pathol. Microbiol. Scand. 53: 217-224.
5. Clague, H. W., M. Harth, D. Hellyer, and W. K. Morgan. 1982. Septic arthritis due to Nocardia asteroides in association with pulmonary alveolar proteinosis. J. Rheumatol. 9: 469-472.
6. Fried, J., D. Hinthorn, J. Ralstin, P. Gerjarusak, and C. Liu. 1988. Cure of brain abscess caused by Nocardia asteroides resistant to multiple antibiotics. South. Med. J. 81: 412-413.
7. Hartung, M., and K. Salfelder. 1975. Pulmonary alveolar proteinosis and his-toplasmosis: report of three cases. Virchows Arch. A Pathol. Anat. Histol. 368: 281-287.
8. Oerlemans, W. G., E. N. Jansen, R. L. Prevo, and M. M. Eijsvogel. 1998. Primary cerebellar nocardiosis and alveolar proteinosis. Acta Neurol. Scand. 97: 138-141.
9. Rosen, S. H., B. Castleman, and A. A. Liebow. 1958. Pulmonary alveolar pro-teinosis. N. Engl. J. Med. 258: 1123-1142.
10. Walker, D. A., and S. M. McMahon. 1986. Pulmonary alveolar proteinosis complicated by cerebral abscess: report of a case. J. Am. Osteopath. Assoc. 86: 447-450.
11. Witty, L. A., V. F. Tapson, and C. A. Piantadosi. 1994. Isolation of mycobacteria in patients with pulmonary alveolar proteinosis. Medicine (Baltimore) 73: 103-109.
12. Golde, D. W., M. Territo, T. N. Finley, and M. J. Cline. 1976. Defective lung macrophages in pulmonary alveolar proteinosis. Ann. Intern. Med. 85: 304-309.
13. Gonzalez-Rothi, R. J., and J. O. Harris. 1986. Pulmonary alveolar proteinosis. Further evaluation of abnormal alveolar macrophages. Chest 90: 656-661.
14. Shibata, Y., P. Y. Berclaz, Z. C. Chroneos, M. Yoshida, J. A. Whitsett, and B. C. Trapnell. 2001. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 15: 557-567.
15. Uchida, K., D. C. Beck, T. Yamamoto, P. Y. Berclaz, S. Abe, M. K. Staudt, B. C. Carey, M. D. Filippi, S. E. Wert, L. A. Denson, et al. 2007. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N. Engl. J. Med. 356: 567-579.
16. Lee, Y. C., G. T. Chew, and B. W. Robinson. 1999. Pulmonary and meningeal cryptococcosis in pulmonary alveolar proteinosis. Aust. N. Z. J. Med. 29: 843-844.
17. Sunderland, W. A., R. A. Campbell, and M. J. Edwards. 1972. Pulmonary alveolar proteinosis and pulmonary cryptococcosis in an adolescent boy. J. Pediatr. 80: 450-456.
18. Browne, S. K., and S. M. Holland. 2010. Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms. Lancet Infect. Dis. 10: 875-885.
19. Doffinger, R., M. R. Helbert, G. Barcenas-Morales, K. Yang, S. Dupuis, L. Ceron-Gutierrez, C. Espitia-Pinzon, N. Barnes, G. Bothamley, J. L. Casanova, et al. 2004. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin. Infect. Dis. 38: e10-e14.
20. Hoflich, C., R. Sabat, S. Rosseau, B. Temmesfeld, H. Slevogt, W. D. Docke, G. Grutz, C. Meisel, E. Halle, U. B. Gobel, et al. 2004. Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood 103: 673-675.
21. Kampmann, B., C. Hemingway, A. Stephens, R. Davidson, A. Goodsall, S. Anderson, M. Nicol, E. Scholvinck, D. Relman, S. Waddell, et al. 2005. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J. Clin. Invest. 115: 2480-2488.
22. Patel, S. Y., L. Ding, M. R. Brown, L. Lantz, T. Gay, S. Cohen, L. A. Martyak, B. Kubak, and S. M. Holland. 2005. Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J. Immunol. 175: 4769-4776.
23. Kisand, K., A. S. Boe Wolff, K. T. Podkrajsek, L. Tserel, M. Link, K. V. Kisand, E. Ersvaer, J. Perheentupa, M. M. Erichsen, N. Bratanic, et al. 2010. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J. Exp. Med. 207: 299-308.
24. Puel, A., R. Doffinger, A. Natividad, M. Chrabieh, G. Barcenas-Morales, C. Picard, A. Cobat, M. Ouachee-Chardin, A. Toulon, J. Bustamante, et al. 2010. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 207: 291-297.
25. Kidd, S. E., F. Hagen, R. L. Tscharke, M. Huynh, K. H. Bartlett, M. Fyfe, L. Macdougall, T. Boekhout, K. J. Kwon-Chung, and W. Meyer. 2004. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc. Natl. Acad. Sci. USA 101: 17258-17263.
26. Mitchell, D. H., T. C. Sorrell, A. M. Allworth, C. H. Heath, A. R. McGregor, K. Papanaoum, M. J. Richards, and T. Gottlieb. 1995. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin. Infect. Dis. 20: 611-616.
27. Pappas, P. G., J. R. Perfect, G. A. Cloud, R. A. Larsen, G. A. Pankey, D. J. Lancaster, H. Henderson, C. A. Kauffman, D. W. Haas, M. Saccente, et al. 2001. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin. Infect. Dis. 33: 690-699.
28. Chau, T. T., N. H. Mai, N. H. Phu, H. D. Nghia, L. V. Chuong, D. X. Sinh, V. A. Duong, P. T. Diep, J. I. Campbell, S. Baker, et al. 2010. A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease. BMC Infect. Dis. 10: 199.
29. Lui, G., N. Lee, M. Ip, K. W. Choi, Y. K. Tso, E. Lam, S. Chau, R. Lai, and C. S. Cockram. 2006. Cryptococcosis in apparently immunocompetent patients. QJM 99: 143-151.
30. Sanchetee, P. 1998. Cryptococcal meningitis in immunocompetent patients. J. Assoc. Physicians India 46: 617-619.
31. Bichile, L. S., Y. A. Gokhale, V. Sridhar, and N. H. Gill. 2001. Disseminated cryptococcal infection in immune competent patients. J. Assoc. Physicians India 49: 377-378.
32. Ding, L., A. Mo, K. Jutivorakool, M. Pancholi, S. M. Holland, and S. K. Browne. 2012. Determination of human anticytokine autoantibody profiles using a particle-based approach. J. Clin. Immunol. 32: 238-245.
33. Holland, S. M., S. E. Dorman, A. Kwon, I. F. Pitha-Rowe, D. M. Frucht, S. M. Gerstberger, G. J. Noel, P. Vesterhus, M. R. Brown, and T. A. Fleisher. 1998. Abnormal regulation of interferon-gamma, interleukin-12, and tumor necrosis factor-alpha in human interferon-gamma receptor 1 deficiency. J. Infect. Dis. 178: 1095-1104.
34. Lee, M. G., H. Spencer, W. F. Clarke, B. N. Rao, M. Lowe, and M. Nelson. 1982. Pulmonary alveolar proteinosis in Jamaica. West Indian Med. J. 31: 103-110.
35. Watanabe, M., K. Uchida, K. Nakagaki, B. C. Trapnell, and K. Nakata. 2010. High avidity cytokine autoantibodies in health and disease: pathogenesis and mechanisms. Cytokine Growth Factor Rev. 21: 263-273.
36. Uchida, K., K. Nakata, T. Suzuki, M. Luisetti, M. Watanabe, D. E. Koch, C. A. Stevens, D. C. Beck, L. A. Denson, B. C. Carey, et al. 2009. Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 113: 2547-2556.
37. Browne, S. K., P. D. Burbelo, P. Chetchotisakd, Y. Suputtamongkol, S. Kiertiburanakul, P. A. Shaw, J. L. Kirk, K. Jutivorakool, R. Zaman, L. Ding, et al. 2012. Adult-onset immunodeficiency in Thailand and Taiwan. N. Engl. J. Med. 367: 725-734.
38. Burbelo, P. D., S. K. Browne, E. P. Sampaio, G. Giaccone, R. Zaman, E. Kristosturyan, A. Rajan, L. Ding, K. H. Ching, A. Berman, et al. 2010. Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood 116: 4848-4858.
39. Chiller, T., K. Farrokhshad, E. Brummer, and D. A. Stevens. 2002. Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on polymorphonuclear neutrophils, monocytes or monocyte-derived macrophages combined with voriconazole against Cryptococcus neoformans. Med. Mycol. 40: 21-26.
40. Tascini, C., A. Vecchiarelli, R. Preziosi, D. Francisci, F. Bistoni, and F. Baldelli. 1999. Granulocyte-macrophage colony-stimulating factor and fluconazole enhance anti-cryptococcal activity of monocytes from AIDS patients. AIDS 13: 49-55.
41. Murphy, J. W., A. Zhou, and S. C. Wong. 1997. Direct interactions of human natural killer cells with Cryptococcus neoformans inhibit granulocyte-macrophage colony-stimulating factor and tumor necrosis factor alpha production. Infect. Immun. 65: 4564-4571.
42. Chen, G. H., J. L. Curtis, C. H. Mody, P. J. Christensen, L. R. Armstrong, and G. B. Toews. 1994. Effect of granulocyte-macrophage colony-stimulating factor on rat alveolar macrophage anticryptococcal activity in vitro. J. Immunol. 152: 724-734.
43. Bhol, K., K. Natarajan, N. Nagarwalla, A. Mohimen, V. Aoki, and A. R. Ahmed. 1995. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc. Natl. Acad. Sci. USA 92: 5239-5243.
44. Browne, S. K., R. Zaman, E. P. Sampaio, K. Jutivorakool, L. B. Rosen, L. Ding, M. J. Pancholi, L. M. Yang, D. Long Priel, G. Uzel, et al. 2012. Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection. Blood 119: 3933-3939.
45. Swanson, S. J., J. Ferbas, P. Mayeux, and N. Casadevall. 2004. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin. Pract. 96: c88-c95.
46. Lipovsky, M. M., A. E. Juliana, G. Gekker, S. Hu, A. I. Hoepelman, and P. K. Peterson. 1998. Effect of cytokines on anticryptococcal activity of human microglial cells. Clin. Diagn. Lab. Immunol. 5: 410-411.
47. Olszewski, M. A., Y. Zhang, and G. B. Huffnagle. 2010. Mechanisms of cryp-tococcal virulence and persistence. Future Microbiol. 5: 1269-1288.
48. Uchida, K., K. Nakata, B. C. Trapnell, T. Terakawa, E. Hamano, A. Mikami, I. Matsushita, J. F. Seymour, M. Oh-Eda, I. Ishige, et al. 2004. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar protei-nosis. Blood 103: 1089-1098.
49. Kavuru, M. S., A. Malur, I. Marshall, B. P. Barna, M. Meziane, I. Huizar, H. Dalrymple, R. Karnekar, and M. J. Thomassen. 2011. An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur. Respir. J. 38: 1361-1367.
50. Kitamura, T., K. Uchida, N. Tanaka, T. Tsuchiya, J. Watanabe, Y. Yamada, K. Hanaoka, J. F. Seymour, O. D. Schoch, I. Doyle, et al. 2000. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am. J. Respir. Crit. Care Med. 162: 658-662.
51. Bhol, K., A. Mohimen, and A. R. Ahmed. 1994. Correlation of subclasses of IgG with disease activity in pemphigus vulgaris. Dermatology 189(Suppl 1): 85-89.
52. Borie, R., M. P. Debray, C. Laine, M. Aubier, and B. Crestani. 2009. Rituximab therapy in autoimmune pulmonary alveolar proteinosis. Eur. Respir. J. 33: 1503-1506.